Cell and Gene Outsourcing

1. From Platform To Patient: Streamlining Gene Therapy Development 12/5/2024

   Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

2. Scale-Up Allogeneic Cell Therapies To Large Patient Populations

   Achieve your therapeutic and commercial goals by utilizing a tried-and-tested standardized approach combined with the latest technology and reliable analytics.

3. Mastering The Art Of Developing A Successful Bispecific Antibody 10/3/2024

   Learn innovative strategies to overcome the complexities of bispecific antibody development, from intelligent design to efficient purification techniques.

4. Expertise In Commercial Fill-Finish For More Than 30 Years 8/5/2024

   Examine how a new high-speed aseptic filling line can help bring your product to market with speed and efficiency while ensuring safety and high product quality.

5. AAV Analytics: Key Considerations When Developing A Clinical Program 4/25/2024

   Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.

6. Critical Supply Chain And Logistics Considerations For Cell And Gene Therapy Management 8/30/2024

   Explore the unique challenges and complexities involved in key CGT logistics areas like donor and patient accessibility, critical raw materials management, and innovative temperature control equipment.

7. Manufacturing Life-Saving Gene Therapies 2/24/2021

   Take a look behind the scenes and hear firsthand about the commitment to patients and clients at Andelyn Biosciences.

8. De-Risk Your Path To Clinic With An AAV Suspension Platform

   Build a reliable, de-risked path to the clinic while avoiding unforeseen costs and compliance-related delays with advice from Suparna Sanyal, PhD, Head of Viral Vectors Commercial Development.

9. Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

   In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

10. The CDMO Value Proposition For Your Autologous Cell Therapy

    This panel session features a decade-long story of partnership in bringing two life-changing gene therapies to market successfully in 2022.